FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2570-2572 December 25, 2003 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Alemtuzumab (Campath-1H) is a humanized monoclonal antibody directed against CD52, a glycosylated peptide antigen that is expressed on normal lymphocytes and highly expressed on chronic lymphocytic leukemia cells. It has been shown to have clinically significant activity in T-cell chronic lymphocytic leukemia. The primary treatment-related adverse event that has been reported is the development of opportunistic infections secondary to the T-cell immunodeficiency.¹

We report a case of an Epstein–Barr virus (EBV)–positive lymphoproliferative disorder occurring after the use of alemtuzumab. An 80-year-old woman had received the diagnosis of CD4-positive T-cell chronic lymphocytic leukemia eight years previously. There was . . . [Full Text of this Article]

This article has been cited by other articles:

• Kluin-Nelemans, H. C., Coenen, J. L., Boers, J. E., van Imhoff, G. W., Rosati, S. (2008). EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 112: 1039-1041 [Abstract] [Full Text]